MarketWatch (press release) Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan -relapsed/refractory metastatic colorectal cancer (Abstract 3621) General poster session, First Author: Neil N. Senzer, M.D., Sunday, June ... and more »
Herald Sun A thumbs up from a safety committee for Alchemia advanced cancer drug HA- Irinotecan leads to a retained speculative buy call. Small mining companies are really doing it tough at the moment. But dormant producer Central Asia Resources is poised for a ... and more »
MarketWatch (press release) Alchemia and Merck Serono have agreed to collaborate by supporting the initiation of a new clinical trial of HA- Irinotecan which will be conducted by Peter Gibbs, Associate Professor at the Walter and Eliza Hall Institute of Medical Research. The ... and more »
MarketWatch (press release) The most frequent adverse reactions seen in patients with EGFR-expressing metastatic colorectal cancer (n=354) treated with ERBITUX plus irinotecan in clinical trials (incidence greater-than or equal to50%) were acneiform rash (88%), asthenia/malaise ... and more »
The Herald | HeraldOnline.com Vectibix was approved in the United States in September 2006 as a single agent for the treatment of patients with EGFR-expressing mCRC with disease progression on or following fluoropyrimidine-, oxaliplatin- and irinotecan -containing chemotherapy ... and more »
Oncology Nurse Advisor The tumor size response metrics were estimated using longitudinal tumor size models and data from two phase III studies comparing bevacizumab plus chemotherapy (fluorouracil, leucovorin, and irinotecan ) vs chemotherapy alone as first-line treatment in ...
